Cited by 1,993Acute Myeloid Leukemia ResearchCancer Genomics and DiagnosticsChromatin Remodeling and Cancer

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

Open access

Ding, Li, Ley, Timothy J., Larson, David E., Miller, Christopher A., Koboldt, Daniel C., Welch, John S., Ritchey, Julie K., Young, Margaret A., Lamprecht, Tamara, McLellan, Michael D., McMichael, Joshua F., Wallis, John W., Lu, Charles, Shen, Dong, Harris, Christopher C., Dooling, David J., Fulton, Robert S., Fulton, Lucinda L., Chen, Ken, Schmidt, Heather, Kalicki-Veizer, Joelle, Magrini, Vincent J., Cook, Lisa, McGrath, Sean D., Vickery, Tammi L., Wendl, Michael C., Heath, Sharon, Watson, Mark A., Link, Daniel C., Tomasson, Michael H., Shannon, William D., Payton, Jacqueline E., Kulkarni, Shashikant, Westervelt, Peter, Walter, Matthew J., Graubert, Timothy A., Mardis, Elaine R., Wilson, Richard K., DiPersio, John F.·2012·Nature

DOI 10.1038/nature10738PMC PMC3267864

Open this paper in CoChat — free account Open PDF

Abstract

The sequencing of AML genomes of eight patients before and after relapse reveals two major patterns of clonal evolution, with chemotherapy appearing to have a role in both patterns. Many patients with acute myeloid leukaemia (AML) achieve remission, but it is often short-lived and the returned disease is usually refractory to therapy. Genome sequencing of eight patients with AML before and after relapse reveals two major patterns of tumour cell evolution. The founding clone survives chemotherapy in all patients, and, in one clonal pattern, it acquires new mutations and expands at relapse. In the other, a subclone surviving from the original tumour expands and then acquires new mutations. Comparisons of relapse-specific and primary tumour mutations point to an increase in transversions, implying DNA damage caused by cytotoxic chemotherapy. This work demonstrates that the AML genome in an individual patient presents a moving target, and highlights the importance of striving to eradicate both the founding clone and all of its subclones. Most patients with acute myeloid leukaemia (AML) die from progressive disease after relapse, which is associated with clonal evolution at the cytogenetic level1,2 . To determine the mutational spectrum associated with relapse, we sequenced the primary tumour and relapse genomes from eight AML patients, and validated hundreds of somatic mutations using deep sequencing; this allowed us to define clonality and clonal evolution patterns precisely at relapse. In addition to discovering novel, recurrently mutated genes (for example, WAC, SMC3, DIS3, DDX41 and DAXX) in AML, we also found two major clonal evolution patterns during AML relapse: (1) the founding clone in the primary tumour gained mutations and evolved into the relapse clone, or (2) a subclone of the founding clone survived initial therapy, gained additional mutations and expanded at relapse. In all cases, chemotherapy failed to eradicate the founding clone. The comparison of relapse-specific versus primary tumour mutations in all eight cases revealed an increase in transversions, probably due to DNA damage caused by cytotoxic chemotherapy. These data demonstrate that AML relapse is associated with the addition of new mutations and clonal evolution, which is shaped, in part, by the chemotherapy that the patients receive to establish and maintain remissions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature10738

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citation
Tumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Self-citation
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Self-citation
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramís, G., Jares, P., Beà, S., González, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,529
BreakDancer: an algorithm for high-resolution mapping of genomic structural variation
Chen, K., Wallis, J. W., McLellan, M. D., Larson, D. E., Kalicki, J. M., Pohl, C. S., McGrath, S. D., Wendl, M. C., Zhang, Q., Locke, D. P., et al. (2009) · Nature Methods · doi:10.1038/nmeth.1363 · Cited by 1,489

Show all 30 references

Sorted by citations

Items 701–800 of 999

Insights into the molecular profiles of adult and paediatric acute myeloid leukaemia
Aung, M. M. K., Mills, M. L., Bittencourt‐Silvestre, J., & Keeshan, K. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12899 · Cited by 42
PHF6 Mutations in Hematologic Malignancies
Kurzer, J. H., & Weinberg, O. K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.704471 · Cited by 41
Distinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classification
Liu, T., Rao, J., Hu, W., Cui, B., Cai, J., Liu, Y., Sun, H., Chen, X., Tang, Y., Chen, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29336-y · Cited by 40
Expression profiling of leukemia patients: Key lessons and future directions
Shivarov, V. S., & Bullinger, L. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.04.006 · Cited by 40
The evolutionary biography of chronic lymphocytic leukemia
Puente, X. S., & López-Otı́n, C. (2013) · Nature Genetics · doi:10.1038/ng.2556 · Cited by 38
A gene expression profile associated with relapse of cytogenetically normal acute myeloid leukemia is enriched for leukemia stem cell genes
Hackl, H., Steinleitner, K., LIND, K., Hofer, S., Tos̆ić, N., Pavlović, S., Suvajdžić, N., Sill, H., & Wieser, R. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.944523 · Cited by 38
DNA methylation in normal and malignant hematopoiesis
Celik, H., Kramer, A. C., & Challen, G. A. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-1957-7 · Cited by 39
Clonal origin and spread of metastatic prostate cancer
Etten, J. L. V., & Dehm, S. M. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0049 · Cited by 40
Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
Luskin, M. R., Carroll, M. P., Lieberman, D. B., Morrissette, J. J. D., Zhao, J., Crisalli, L. M., Roth, D. B., Luger, S. M., Porter, D., & Reshef, R. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.07.018 · Cited by 39
High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells
Gerby, B., Veiga, D. F. T., Krošl, J., Nourreddine, S., Ouellette, J., Haman, A., Lavoie, G., Fares, I., Tremblay, M. R., Litalien, V., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86489 · Cited by 37
Assessment of T-cell receptor repertoire and clonal expansion in peripheral T-cell lymphoma using RNA-seq data
Gong, Q., Wang, C., Zhang, W., Iqbal, J., Hu, Y., Greiner, T. C., Cornish, A. S., Kim, J.-H., Rabadán, R., Abate, F., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11310-0 · Cited by 38
Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling
Tarlock, K., Zhong, S., He, Y., Ries, R. E., Severson, E. A., Bailey, M., Morley, S., Balasubramanian, S., Erlich, R., Lipson, D., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25443 · Cited by 41
Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms
Carbonell, D., Suárez‐González, J., Chicano, M., Andrés-Zayas, C., Triviño, J. C., Rodríguez‐Macías, G., Bastos‐Oreiro, M., Font, P., Ballesteros, M., Muñiz, P., et al. (2019) · Cancers · doi:10.3390/cancers11091364 · Cited by 38
Differential gene expression analysis of HNSCC tumors deciphered tobacco dependent and independent molecular signatures
Shaikh, I., Ansari, A., Ayachit, G., Gandhi, M., Sharma, P., Bhairappanavar, S. B., Joshi, C. G., & Das, J. (2019) · Oncotarget · doi:10.18632/oncotarget.27249 · Cited by 41
Optical Genome Mapping as a Diagnostic Tool in Pediatric Acute Myeloid Leukemia
Suttorp, J., Lühmann, J. L., Behrens, Y. L., Göhring, G., Steinemann, D., Reinhardt, D., Neuhoff, N. V., & Schneider, M. (2022) · Cancers · doi:10.3390/cancers14092058 · Cited by 38
Insertions and Deletions (Indels)
Sehn, J. K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404748-8.00009-5 · Cited by 49
Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation
Zhang, Z., Hasegawa, Y., Hashimoto, D., Senjo, H., Kikuchi, R., Chen, X., Yoneda, K., Sekiguchi, T., Kawase, T., Tsuzuki, H., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01619-4 · Cited by 38
SCNVSim: somatic copy number variation and structure variation simulator
Qin, M., Liu, B., Conroy, J. M., Morrison, C. D., Hu, Q., Cheng, Y., Murakami, M., Odunsi, A., Johnson, C. S., Wei, L., et al. (2015) · BMC Bioinformatics · doi:10.1186/s12859-015-0502-7 · Cited by 38
Epigenetic regulation of GATA2 and its impact on normal karyotype acute myeloid leukemia
Celton, M., Forest, A., Gosse, G., Lemieux, S., Hébert, J., Sauvageau, G., & Wilhelm, B. T. (2014) · Leukemia · doi:10.1038/leu.2014.67 · Cited by 37
Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells
Zhang, Y., Yan, X., Sashida, G., Zhao, X., Rao, Y., Goyama, S., Whitman, S. P., Zorko, N. A., Bernot, K. M., Conway, R. M., et al. (2012) · Blood · doi:10.1182/blood-2012-02-412379 · Cited by 39
Spatial and temporal cancer evolution: causes and consequences of tumour diversity
Hiley, C. T., & Swanton, C. (2014) · Clinical Medicine · doi:10.7861/clinmedicine.14-6-s33 · Cited by 39
Therapeutic targeting of leukemic stem cells in acute myeloid leukemia – the biological background for possible strategies
Bruserud, Ø., Aasebø, E., Hernandez-Valladares, M., Tsykunova, G., & Reikvam, H. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1356818 · Cited by 38
Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma
Bochtler, T., Merz, M., Hielscher, T., Granzow, M., Hoffmann, K., Krämer, A., Raab, M. S., Hillengaß, J., Seckinger, A., Kimmich, C. R., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018023200 · Cited by 37
Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism
Castelli, G., Pelosi, E., & Testa, U. (2019) · Cancers · doi:10.3390/cancers11020260 · Cited by 39
Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer
Bueschbell, B., Caniceiro, A. B., Suzano, P. M. S., Machuqueiro, M., Rosário‐Ferreira, N., & Moreira, I. S. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100811 · Cited by 38
Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives
Bouligny, I. M., Maher, K. R., & Grant, S. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100996 · Cited by 43
ReMixT: clone-specific genomic structure estimation in cancer
McPherson, A., Roth, A. J. L., Ha, G., Chauve, C., Steif, A., de Souza, C. P. E., Eirew, P. D., Bouchard‐Côté, A., Aparicio, S. A. J. R., Şahinalp, S. C., et al. (2017) · Genome biology · doi:10.1186/s13059-017-1267-2 · Cited by 36
Back to the Future! The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation
Hourigan, C. S., McCarthy, P. L., & Lima, M. J. G. D. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.11.017 · Cited by 36
Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022
Roloff, G. W., Odenike, O. M., Bajel, A. R., Wei, A. H., Foley, N. C., & Uy, G. L. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349605 · Cited by 36
HIRA vs. DAXX: the two axes shaping the histone H3.3 landscape
Choi, J., Kim, T., & Cho, E. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01145-3 · Cited by 41
Synthetic lethality and cancer: cohesin and PARP at the replication fork
O’Neil, N. J., van Pel, D. M., & Hieter, P. (2013) · Trends in Genetics · doi:10.1016/j.tig.2012.12.004 · Cited by 42
Biased estimates of clonal evolution and subclonal heterogeneity can arise from PCR duplicates in deep sequencing experiments
Smith, E. N., Jepsen, K., Khosroheidari, M., Rassenti, L. Z., D’Antonio, M., Ghia, E. M., Carson, D. A., Jamieson, C. H. M., Kipps, T. J., & Frazer, K. A. (2014) · Genome biology · doi:10.1186/preaccept-1251182501124451 · Cited by 35
Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing
Wang, B., Liu, Y., Hou, G., Wang, L., Lv, N., Xu, Y., Xu, Y., Wang, X., Xuan, Z., Jing, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7028 · Cited by 35
Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML
Li, S., Chen, X., Wang, J., Meydan, C., Glass, J. L., Shih, A. H., Delwel, R., Levine, R. L., Mason, C. E., & Melnick, A. M. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0897 · Cited by 35
When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter
Roloff, G. W., & Griffiths, E. A. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020206 · Cited by 36
Detectable Clonal Mosaicism in the Human Genome
Machiela, M. J., & Chanock, S. J. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.09.001 · Cited by 36
Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes
Nazha, A., Seastone, D. J., Radivoyevitch, T., Przychodzen, B. P., Carraway, H. E., Patel, B. J., Carew, J. S., Makishima, H., Sekeres, M. A., & Maciejewski, J. P. (2015) · Haematologica · doi:10.3324/haematol.2015.130112 · Cited by 36
densityCut: an efficient and versatile topological approach for automatic clustering of biological data
Ding, J., Shah, S. P., & Condon, A. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw227 · Cited by 38
Gene‐dosage dependent overexpression at the 13q amplicon identifies DIS3 as candidate oncogene in colorectal cancer progression
de Groen, F. L. M., Krijgsman, O., Tijssen, M., Vriend, L. E. M., Ylstra, B., Hooijberg, E., Meijer, G. A., Steenbergen, R. D. M., & Carvalho, B. G. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22144 · Cited by 35
Advances in treating acute myeloid leukemia
Showel, M. M., & Levis, M. J. (2014) · F1000Prime Reports · doi:10.12703/p6-96 · Cited by 34
The evolving contribution of hematopoietic progenitor cells to lymphomagenesis
Weigert, O., & Weinstock, D. M. (2012) · Blood · doi:10.1182/blood-2012-05-414995 · Cited by 40
MAD Bayes for Tumor Heterogeneity—Feature Allocation With Exponential Family Sampling
Xu, Y., Müller, P., Yuan, Y., Gulukota, K., & Ji, Y. (2015) · Journal of the American Statistical Association · doi:10.1080/01621459.2014.995794 · Cited by 35
Can we deconstruct cancer, one patient at a time?
Blau, C. A., & Liakopoulou, E. (2012) · Trends in Genetics · doi:10.1016/j.tig.2012.09.004 · Cited by 34
Acute Myeloid Leukemia: Past, Present, and Prospects for the Future
Short, N. J., & Ravandi, F. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.02.007 · Cited by 34
Emergence of heterogeneity in acute leukemias
Stiehl, T., Lutz, C., & Marciniak-Czochra, A. K. (2016) · Biology Direct · doi:10.1186/s13062-016-0154-1 · Cited by 34
Progress in RNAi-mediated Molecular Therapy of Acute and Chronic Myeloid Leukemia
Landry, B. K., Valencia‐Serna, J., Gül-Uludağ, H., Jiang, X., Janowska‐Wieczorek, A., Brandwein, J. M., & Uludağ, H. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.13 · Cited by 35
Combination therapies and intra-tumoral competition: Insights from mathematical modeling
Piretto, E., Delitala, M. E., & Ferraro, M. (2018) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2018.03.014 · Cited by 34
Acute myeloid/T‐lymphoblastic leukaemia ( AMTL ): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy
Gutiérrez, A., & Kentsis, A. (2018) · British Journal of Haematology · doi:10.1111/bjh.15129 · Cited by 35
Clonal Evolution and Changes in Two AML Patients Detected with A Novel Single-Cell DNA Sequencing Platform
Xu, L., Durruthy-Durruthy, R., Eastburn, D. J., Pellegrino, M., Shah, O., Meyer, E. H., & Zehnder, J. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-47297-z · Cited by 36
Applications of Next Generation Sequencing to the Analysis of Familial Breast/Ovarian Cancer
Zelli, V., Compagnoni, C., Cannita, K., Capelli, R., Capalbo, C., Nolfi, M. D. V., Alesse, E., Zazzeroni, F., & Tessitore, A. (2020) · Microarrays · doi:10.3390/ht9010001 · Cited by 40
Genomic analysis of biomarkers related to the prognosis of acute myeloid leukemia
Li, G., Gao, Y., Li, K., Lin, A., & Jiang, Z. (2020) · Oncology Letters · doi:10.3892/ol.2020.11700 · Cited by 35
Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells
Tremblay, C. S., Chiu, S. K., Saw, J., McCalmont, H., Litalien, V., Boyle, J. A., Sonderegger, S., Chau, N., Evans, K., Cerruti, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20091-6 · Cited by 37
Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer
Khella, C. A., Mehta, G. A., Mehta, R. N., & Gatza, M. L. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020149 · Cited by 35
Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells
Kawashima, N., Ishikawa, Y., Kim, J. H., Ushijima, Y., Akashi, A., Yamaguchi, Y., Hattori, H., Nakashima, M., Ikeno, S., Kihara, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29304-6 · Cited by 38
Chromatin structure in cancer
Wang, M., Sunkel, B. D., Ray, W. C., & Stanton, B. Z. (2022) · BMC Molecular and Cell Biology · doi:10.1186/s12860-022-00433-6 · Cited by 37
Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease
Natarajan, P. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318181 · Cited by 35
How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?
Patel, J. P., & Levine, R. L. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.28.3797923 · Cited by 37
Genomic sequencing in cancer
Tuna, M., & Amos, C. I. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.11.004 · Cited by 37
RNA Exosome Regulates AID DNA Mutator Activity in the B Cell Genome
Pefanis, E., & Basu, U. (2015) · Advances in immunology · doi:10.1016/bs.ai.2015.04.002 · Cited by 39
Acute Myeloid and Lymphoblastic Leukemia Cell Interactions with Endothelial Selectins: Critical Role of PSGL-1, CD44 and CD43
Spertini, C., Baïsse, B., Bellone, M., Gikic, M., Смирнова, Т. А., & Spertini, O. (2019) · Cancers · doi:10.3390/cancers11091253 · Cited by 35
Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy
Coorens, T. H. H., Collord, G., Treger, T. D., Adams, S. P., Mitchell, E., Newman, B., Getz, G. A., Godfrey, A. L., Bartram, J. L., & Behjati, S. (2023) · Nature Cancer · doi:10.1038/s43018-023-00604-0 · Cited by 37
The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia
Ouyang, J., Goswami, M., Tang, G., Peng, J., Ravandi, F., Daver, N. G., Routbort, M. J., Konoplev, S. N., Lin, P., Medeiros, L. J., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.23988 · Cited by 34
Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression
Beer, P. A., Knapp, D. J. H. F., Miller, P. H., Kannan, N., Sloma, I., Heel, K., Babovic, S., Bulaeva, E., Rabu, G. M., Terry, J., et al. (2014) · Blood · doi:10.1182/blood-2014-06-581173 · Cited by 34
A multigene array for measurable residual disease detection in AML patients undergoing SCT
Goswami, M., McGowan, K. S., Lu, K. Y., Jain, N. A., Candia, J., Hensel, N. F., Tang, J., Calvo, K. R., Battiwalla, M., Barrett, A. J., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.326 · Cited by 34
Translating Genomics to the Clinic: Implications of Cancer Heterogeneity
Samuel, N., & Hudson, T. J. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.184580 · Cited by 34
Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells
Dulphy, N., Chrétien, A.-S., Khaznadar, Z., Fauriat, C., Nanbakhsh, A., Caignard, A., Chouaı̈b, S., Olive, D., & Toubert, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00094 · Cited by 39
Cytosolic Nucleic Acid Sensors in Inflammatory and Autoimmune Disorders
Khan, S., Godfrey, V., & Zaki, H. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.10.002 · Cited by 34
CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells
Touzet, L., Dumézy, F., Roumier, C., Berthon, C., Bories, C., Quesnel, B., Preudhomme, C., & Boyer, T. (2019) · Cancer Medicine · doi:10.1002/cam4.2007 · Cited by 34
CGRP Signaling via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid Leukemia
Glüxam, T., Grandits, A. M., Schlerka, A., Nguyen, C. H., Etzler, J., Finkes, T., Fuchs, M., Scheid, C., Heller, G., Hackl, H., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235826 · Cited by 35
Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies
Thomas, M., Sukhai, M. A., Zhang, T., Dolatshahi, R., Harbi, D., Garg, S., Misyura, M., Pugh, T. J., Stockley, T. L., & Kamel‐Reid, S. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0547-ra · Cited by 34
BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor
Eckel‐Passow, J. E., Serie, D., Cheville, J. C., Ho, T. H., Kapur, P., Brugarolas, J., Thompson, R. H., Leibovich, B. C., Kwon, E. D., Joseph, R. W., et al. (2017) · BMC Urology · doi:10.1186/s12894-017-0209-3 · Cited by 35
Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML)Preprint
Mitchell, K., & Steidl, U. G. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036251 · Cited by 37
Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation
Xiao, H., Wang, L., Luo, Y., Lai, X., Li, C., Shi, J., Tan, Y., Fu, S., Wang, Y., Zhu, N., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6259 · Cited by 33
Exosome substrate targeting: the long and short of it
Mitchell, P. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140088 · Cited by 33
Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes
Fernández‐Mercado, M., Burns, A., Pellagatti, A., Giagounidis, A. A. N., Germing, U., Agirre, X., Prósper, F., Aul, C., Killick, S. B., Wainscoat, J. S., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.086686 · Cited by 33
Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing
Masetti, R., Castelli, I., Astolfi, A., Bertuccio, S. N., Indio, V., Togni, M., Belotti, T., Serravalle, S., Tarantino, G., Zecca, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10778 · Cited by 33
Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes
Waalkes, A., Penewit, K. M., Wood, B. L., Wu, D., & Salipante, S. J. (2017) · Haematologica · doi:10.3324/haematol.2017.169136 · Cited by 33
When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter
Roloff, G. W., & Griffiths, E. A. (2018) · Hematology · doi:10.1182/asheducation-2018.1.35 · Cited by 34
A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality
Parameswaran, S., Kundapur, D., Vizeacoumar, F. S., Freywald, A., Uppalapati, M., & Vizeacoumar, F. J. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.11.001 · Cited by 34
Transcriptional networks in acute myeloid leukemia
Thoms, J. A. I., Beck, D., & Pimanda, J. E. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22794 · Cited by 33
Evolution and Impact of Subclonal Mutations in Papillary Thyroid Cancer
Masoodi, T., Siraj, A. K., Siraj, S., Azam, S., Qadri, Z., Parvathareddy, S. K., Al-Sobhi, S. S., Aldawish, M., Alkuraya, F. S., & Al-Kuraya, K. S. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.09.026 · Cited by 32
Genetic heterogeneity and clonal evolution in acute myeloid leukemia
Romer-Seibert, J. S., & Meyer, S. E. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000626 · Cited by 33
SACY-1 DEAD-Box Helicase Links the Somatic Control of Oocyte Meiotic Maturation to the Sperm-to-Oocyte Switch and Gamete Maintenance inCaenorhabditis elegans
Kim, S., Govindan, J. A., Tu, Z. J., & Greenstein, D. (2012) · Genetics · doi:10.1534/genetics.112.143271 · Cited by 33
DNA damage accumulation and repair defects in FLT3‐ITD acute myeloid leukemia: Implications for clonal evolution and disease progression
Lagunas‐Rangel, F. A. (2022) · Hematological Oncology · doi:10.1002/hon.3076 · Cited by 30
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)
Tiong, I. S., Hiwase, D., Abro, E. U., Bajel, A. R., Palfreyman, E., Beligaswatte, A. M., Reynolds, J., Anstee, N. S., Nguyen, T., Loo, S., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01599 · Cited by 32
The 3'-5' exoribonuclease Dis3 regulates the expression of specific microRNAs inDrosophilawing imaginal discs
Towler, B. P., Jones, C. I., Viegas, S. C., Apura, P., Waldron, J. A., Smalley, S., Arraiano, C. M., & Newbury, S. F. (2015) · RNA Biology · doi:10.1080/15476286.2015.1040978 · Cited by 32
Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis
Ray, M., Goldstein, S., Zhou, S., Potamousis, K. D., Sarkar, D., Newton, M. A., Esterberg, E. J., Kendziorski, C. M., Bögler, O., & Schwartz, D. C. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-505 · Cited by 32
Focal overexpression of CEACAM6 contributes to enhanced tumourigenesis in head and neck cancer via suppression of apoptosis
Cameron, S. R., de Long, L. M., Hazar-Rethinam, M. H., Topkas, E., Endo‐Munoz, L., Cumming, A., Gannon, O. M., Guminski, A. D., & Saunders, N. A. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-74 · Cited by 32
Mass Spectrometry Imaging for the Investigation of Intratumor Heterogeneity
Balluff, B., Hanselmann, M., & Heeren, R. M. A. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.11.008 · Cited by 34
Criticality in tumor evolution and clinical outcome
Persi, E., Wolf, Y. I., Leiserson, M. D. M., Koonin, E. V., & Ruppin, E. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807256115 · Cited by 34
Pediatric myeloid sarcoma: a single institution clinicopathologic and molecular analysis
Zhou, T., Bloomquist, M. S., Ferguson, L. S., Reuther, J., Marcogliese, A. N., Elghetany, M. T., Roy, A., Rao, P. H., Lopez-Terrada, D. H., Redell, M. S., et al. (2019) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2019.1683107 · Cited by 33
Prognosis and outcome of patients with acute myeloid leukemia based on FLT3‑ITD mutation with or without additional abnormal cytogenetics
Tao, S., Wang, C., Chen, Y., Deng, Y., Song, L., Shi, Y., Ling, L., Ding, B., He, Z., & Yu, L. (2019) · Oncology Letters · doi:10.3892/ol.2019.11051 · Cited by 32
AML through the prism of molecular genetics
Charrot, S., Armes, H., Rio‐Machín, A., & Fitzgibbon, J. (2019) · British Journal of Haematology · doi:10.1111/bjh.16356 · Cited by 33
Loss of TET2 Affects Proliferation and Drug Sensitivity through Altered Dynamics of Cell-State Transitions
Morinishi, L. S., Kochanowski, K., Levine, R. L., Wu, L. F., & Altschuler, S. J. (2020) · Cell Systems · doi:10.1016/j.cels.2020.06.003 · Cited by 32
Post-transcriptional control of cellular differentiation by the RNA exosome complex
de Andrade, I. F., Mehta, C., & Bresnick, E. H. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa883 · Cited by 31
Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model
Stroopinsky, D., Liegel, J. J., Bhasin, M., Cheloni, G., Thomas, B., Bhasin, S. S., Panchal, R., Ghiasuddin, H., Rahimian, M., Nahas, M. R., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.259457 · Cited by 32
Technological readiness and implementation of genomic‐driven precision medicine for complex diseases
Franks, P. W., Melén, E., Friedman, M., Sundström, J., Kockum, I. S., Klareskog, L., Almqvist, C., Bergen, S. E., Czene, K., Hägg, S., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13330 · Cited by 34
Synthesis of 2H-Imidazo[2′,1':2,3] [1,3]thiazolo[4,5-e]isoindol-8-yl-phenylureas with promising therapeutic features for the treatment of acute myeloid leukemia (AML) with FLT3/ITD mutations
Cilibrasi, V., Spanò, V., Bortolozzi, R., Barreca, M., Raimondi, M. V., Rocca, R., Maruca, A., Montalbano, A., Alcaro, S., Ronca, R., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114292 · Cited by 32
Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies
Fukuhara, S., Oshikawa‐Kumade, Y., Kogure, Y., Shingaki, S., Kariyazono, H., Kikukawa, Y., Koya, J., Saito, Y., Tabata, M., Yoshifuji, K., et al. (2022) · Cancer Science · doi:10.1111/cas.15427 · Cited by 32
Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy
Zhang, W., Yu, G., Zhang, H., Basyal, M., Ly, C., Yuan, B., Ruvolo, V. R., Piya, S., Bhattacharya, S., Zhang, Q., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.280884 · Cited by 35

Authors: Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., McMichael, J. F., Wallis, J. W., Lu, C., Shen, D., Harris, C. C., Dooling, D. J., Fulton, R. S., Fulton, L. L., Chen, K., Schmidt, H., Kalicki-Veizer, J., Magrini, V. J., Cook, L., McGrath, S. D., Vickery, T. L., Wendl, M. C., Heath, S., Watson, M. A., Link, D. C., Tomasson, M. H., Shannon, W. D., Payton, J. E., Kulkarni, S., Westervelt, P., Walter, M. J., Graubert, T. A., Mardis, E. R., Wilson, R. K., & DiPersio, J. F.
Affiliations: Washington University in St. Louis (US)
Corresponding author: Ley, Timothy J.
ORCID: Ding, Li
Ley, Timothy J.
Larson, David E.
Miller, Christopher A.
Koboldt, Daniel C.
Welch, John S.
Ritchey, Julie K.
McLellan, Michael D.
McMichael, Joshua F.
Lu, Charles
Shen, Dong
Fulton, Robert S.
Fulton, Lucinda L.
Chen, Ken
Magrini, Vincent J.
McGrath, Sean D.
Vickery, Tammi L.
Wendl, Michael C.
Heath, Sharon
Watson, Mark A.
Link, Daniel C.
Tomasson, Michael H.
Payton, Jacqueline E.
Kulkarni, Shashikant
Walter, Matthew J.
Graubert, Timothy A.
Mardis, Elaine R.
Wilson, Richard K.
DiPersio, John F.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2012-01
Volume: 481
Issue: 7382
Pages: 506-510
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature10738
PMC: PMC3267864
OpenAlex: W2093144236
Cited by: 1,993
References: 30
Citations by year: 2026: 55 · 2025: 50 · 2024: 61 · 2023: 74 · 2022: 116 · 2021: 138 · 2020: 134 · 2019: 151 · 2018: 155 · 2017: 160 · 2016: 197 · 2015: 192 · 2014: 210 · 2013: 182 · 2012: 118
FWCI: 149.48
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-sa
creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
Locations: Nature (publishedVersion, cc-by-nc-sa)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Foundation for Barnes-Jewish Hospital (00335-0505-02)
National Human Genome Research Institute (U54HG003079, HG003079, NHGRI U54 HG003079)
National Cancer Institute (PO1CA101937, CA101937, P01CA101937)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: acute myeloid leukemia, relapse, clonal evolution, somatic mutations, subclones, chemotherapy-induced DNA damage, transversions, recurrently mutated genes, WAC, SMC3, DIS3, DDX41, DAXX, clonality
MeSH terms: Antineoplastic Agents, Clone Cells, DNA Damage, DNA Mutational Analysis, Humans, Recurrence, Reproducibility of Results, Leukemia, Myeloid, Acute, Genome, Human, Mutagenesis, Genes, Neoplasm, High-Throughput Nucleotide Sequencing, Clonal Evolution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks